Update on Buntanetap Phase II/III Alzheimer's Trial Data

Annovis Bio, Inc., a company focused on developing treatments for neurodegenerative disorders, has reported the completion of data cleaning for its phase II/III clinical trial of buntanetap, a drug designed to treat Alzheimer's disease (AD). The company is now preparing for the statistical analysis of the data, with key findings anticipated to be released in April.

The phase II/III trial was a randomized, double-blind, and placebo-controlled study that aimed to evaluate the efficacy, safety, and tolerability of buntanetap in individuals with mild to moderate AD. The trial involved a dose-ranging approach, with participants receiving either 7.5mg, 15mg, or 30mg of buntanetap or a placebo alongside their standard care for a duration of 12 weeks. Out of over 700 screened patients, 353 were enrolled, and 327 successfully completed the study.

Buntanetap is a novel drug candidate that targets the inhibition of multiple neurotoxic proteins, including amyloid beta, tau, alpha synuclein, and TDP43. This approach is intended to improve synaptic transmission, axonal transport, and address neuroinflammation, which are all critical factors in the progression of neurodegeneration associated with AD. The drug has the potential to reverse the neurodegenerative process in Alzheimer's disease by modulating these pathways.

Annovis Bio, headquartered in Malvern, Pennsylvania, is a clinical-stage company that is dedicated to addressing the challenges of neurodegeneration, including AD and Parkinson's Disease (PD). The company is unique in its pursuit to develop a drug that can treat both AD and PD by targeting more than one neurotoxic protein, with the ultimate goal of restoring axonal and synaptic activity. This approach is aimed at improving brain function and treating memory loss, dementia, and the associated dysfunctions in both AD and PD.

The company's leadership expressed gratitude to the participants, their caregivers, and families for their involvement and support in the trial. They also acknowledged the contributions of their study partners, whose teamwork and dedication were instrumental in completing the study efficiently.

Annovis Bio is committed to advancing its drug platform and is eager to share the topline results of the buntanetap trial next month, as they continue their mission to develop innovative therapies for neurodegenerative diseases.